Annual Report 2024
Released
Released
Announcement PDF
ANNUAL
REPORT
2024
An Alternate Future
Alterity Therapeutics Limited
ACN 080 699 065
Lodged with the ASX under Listing Rule 4.3A.
This information should be read in conjunction with the Annual report.
Alterity Therapeutics Limited
ACN 080 699 065
Annual report – June 30, 2024
CONTENTS
CHAIRMAN’S LETTER
i
FORM 20-F
1
SHAREHOLDER INFORMATION
83
CORPORATE DIRECTORY
86
CHAIRMAN’S LETTER
Dear Shareholders,
I am excited to present the Alterity Therapeutics’ Annual Report as we made tremendous progress
over the last year.
MSA Program Hits Several Key Milestones
We currently have three programs ongoing targeting the rare, parkinsonian disorder known as Multiple
System Atrophy (MSA). MSA is an extremely debilitating disease with no approved treatments to
address the underlying condition. Our team is looking to change that paradigm in a truly meaningful
way.
First, we started our MSA program by running a natural history study with our esteemed colleagues at
Vanderbilt University in the U.S. This study is concluding and we are analyzing the trajectory of
disease severity in the enrolled patients to garner a deeper understanding of MSA on multiple levels
including key biomarkers, MRI data, and clinical outcomes. Impressively, as we announced in May
2024, the team has utilized machine learning (a form of artificial intelligence) to optimize specialized
MRI methods for measuring brain iron and brain volumes with precision. With the use of this
technology, the team has developed a novel imaging biomarker to assess brain volume in MSA
affected regions. The bioMUSE data showed a statistically significant increase in iron over 12 months
in the substantia nigra, and statistically significant decreases in brain volume observed in affected
regions at 12 months. These findings, alongside additional biomarker data presented during the year
have informed both of our Phase 2 clinical trials to ensure that we are enrolling the right patients who
may receive the most benefit from our lead asset, ATH434.
ATH434 is currently in two Phase 2 clinical trials in MSA in both early and more advanced patients.
This approach will provide data on patients with differing levels of severity as we look to advance the
asset into pivotal trials.
Our key Phase 2 study is a randomized, double-blind, placebo-controlled trial that enrolled 77 adults
with early-stage MSA known as ATH434-201. In November 2023, we announced completion of
enrollment in this study and in May 2024 the Independent Data Monitoring Committee completed its
third prespecified review of unblinded clinical trial data. Consistent with the first two reviews, the DMC
expressed no concerns about safety and recommended that the study continue as planned without
modification. This recommendation is important for a chronic treatment as participants are able to
safely tolerate ATH434 as their time on study increases. The ATH434-201 trial remains on track and is
expected to be completed in November 2024 with topline data expected in January 2025.
Subsequent to the end of the fiscal year, we reported positive interim data from our open-label
biomarker trial in MSA patients with more advanced disease, known as ATH434-202. After six months
of treatment, 43% of participants showed improvement on the Unified MSA Rating Scale (UMSARS),
indicating reduced disability on activities of daily living. Over the same period, 29% of participants had
stable or improved neurological symptoms (clinical responders) as assessed by the global impression
of change by both the treating physician and the patient. Importantly, the clinical responders on
average had reduced accumulation of iron on MRI in key brain regions including the substantia nigra,
putamen and globus pallidus, as well as stable levels of Neurofilament Light Chain (NFL), a marker of
neuronal injury, when compared to participants who declined. While these preliminary findings are in a
small number of patients, we are extremely encouraged by these early results.
i
Promising Non-Clinical Data in Parkinson’s Disease
We remain excited about the data we reported in December 2023 showing for the first time that
ATH434 can reduce Parkinson’s symptoms in a higher order animal, the monkey, with symptoms that
closely parallel human disease. The data showed that the improvements in motor skills and general
functioning were associated with reductions in iron in affected brain regions, validating the approach
we are using in our ongoing clinical trials. The data from this study improve our ability to predict
clinical outcomes and increases our confidence level in our ongoing Phase 2 clinical trials in Multiple
System Atrophy
Maintaining a Strong Presence at Medical and Scientific Meetings
During the year, we made multiple data presentations at prominent scientific meetings on ATH434, the
bioMUSE study, and our clinical trials. These included the annual meetings for the American Academy
of Neurology (AAN), the American Autonomic Society (AAS), the Society for Neuroscience, and the
International Congress of Parkinson’s Disease and Movement Disorders (MDS). These events continue
to generate excitement about ATH434 within the medical and scientific community about the approach
we are taking to treat Parkinson’s disease and related disorders.
Looking Ahead
We have an exciting year ahead particularly with the topline data expected from both of our Phase 2
clinical programs.
On behalf of the Board of Directors, I would like to extend our gratitude to the Alterity team and to the
individuals who have participated in our development programs. I would also thank our shareholders
for their continued support as we remain committed to creating an alternative future for people living
with neurodegenerative diseases.
Sincerely,
Geoffrey Kempler
Chairman and Founder
ii
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 20-F
☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended June 30, 2024
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
OR
☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report ___________
Commission file number 000-49843
ALTERITY THERAPEUTICS LIMITED
(Exact name of Registrant as specified in its charter and translation of Registrant’s name into English)
Australia
(Jurisdiction of incorporation or organization)
Level 14, 350 Collins Street, Melbourne, VIC 3000, Australia
(Address of principal executive offices)
David Stamler, Chief Executive Officer
Level 14, 350 Collins Street, Melbourne, VIC 3000, Australia
+61 3 9349 4906 (phone)
(Name, telephone, e-mail and/or facsimile number and address of company contact person)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class
American Depositary Shares, each
representing 600 Ordinary Shares
Trading Symbol
ATHE
Name of each exchange on which registered
NASDAQ Capital Market
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual
report:
Ordinary Shares, as of June 30, 2024 5,245,115,318
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ☐ No ☒
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.
Yes ☐ No ☒
Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934 from their obligations under those Sections.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Emerging growth company ☐
Accelerated filer ☐
Non-accelerated filer ☒
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the
Exchange Act. ☐
† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting
Standards Codification after April 5, 2012.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal
control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the
filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive based compensation
received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
U.S. GAAP ☐
International Financial Reporting Standards as issued by the International
Accounting Standards Board ☒
Other ☐
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to
follow:
Item 17 ☐ Item 18 ☐
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
This Annual Report on Form 20-F is incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-228671, 333-248980 and
333-251073) and our Registration Statements on Form F-3 (File Nos. 333-274816, 333-250076 and 333-251647).
INTRODUCTION
Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) was incorporated under the laws of the Commonwealth of Australia on
November 11, 1997. Our mission is to develop therapeutic drugs designed to treat neurogenerative diseases, currently focusing on Parkinsonian and other
movement disorders.
The principal listing of our ordinary shares and listed options to purchase our ordinary shares is on the Australian Securities Exchange, or ASX.
Since September 5, 2002, our American Depository Shares, or ADSs, have traded on the NASDAQ Capital Market under the symbol “PRAN.” On April
8, 2019, we changed our name to Alterity Therapeutics Limited and our ADSs have traded under the symbol “ATHE” since that date. The Bank of New
York, acting as depositary, issues American Depository Receipts, or ADRs, each of which evidences an ADS, which in turn represents 600 of our
ordinary shares. As used in this annual report, the terms “we,” “us,” “our”, “the Company”, “the Group” and “Alterity” mean Alterity Therapeutics
Limited and its subsidiaries, unless otherwise indicated.
Our consolidated financial statements appearing in this annual report are prepared in Australian dollars and in accordance with the International
Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB and Australian equivalents to International
Financial Reporting Standards as issued by the Australian Accounting Standards Board.
Australian Disclosure Requirements
Our ordinary shares are primarily quoted on the Australian Securities Exchange (“ASX”) in addition to our listing of our ADSs on the Nasdaq
Capital Market. As part of our ASX listing, we are required to comply with various disclosure requirements as set out under the Australian Corporations
Act 2001 and the ASX Listing Rules. Information furnished under the sub-heading “Australian Disclosure Requirements” is intended to comply with the
ASX Listing Rules and Corporations Act 2001 disclosure requirements and is not intended to fulfill information required by this Annual Report on Form
20-F.
In this annual report, all references to “U.S. dollars” or “U.S.$” are to the currency of the United States, and all references to “Australian dollars”
or “A$” are to the currency of Australia.
Statements made in this annual report concerning the contents of any contract, agreement or other document are summaries of such contracts,
agreements or documents and are not complete descriptions of all of their terms. If we filed any of these documents as an exhibit to this annual report or
to any registration statement or annual report that we previously filed, you may read the document itself for a complete description of its terms.
Forward-Looking Statements
Except for the historical information contained in this annual report, the statements contained in this annual report are “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, or the Exchange Act, and the Private Securities Litigation Reform Act of 1995, as amended, with respect to our business, financial condition
and results of operations. Such forward-looking statements reflect our current view with respect to future events and financial results. We urge you to
consider that statements which use the terms “anticipate,” “believe,” “do not believe,” “expect,” “plan,” “intend,” “estimate,” and similar expressions are
intended to identify forward-looking statements. We remind readers that forward-looking statements are merely predictions and therefore inherently
subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity, or our
achievements, or industry results, to be materially different from any future results, performance, levels of activity, or our achievements expressed or
implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as
of the date hereof. Except as required by applicable law, including the securities laws of the United States, we undertake no obligation to publicly release
any update or revision to any forward-looking statements to reflect new information, future events or circumstances, or otherwise after the date hereof.
We have attempted to identify significant uncertainties and other factors affecting forward-looking statements in the Risk Factors section that appears in
Item 3.D. “Key Information-Risk Factors.”
TABLE OF CONTENTS
Page
PART I
1
ITEM 1.
ITEM 2.
ITEM 3.
A.
B.
C.
D.
ITEM 4.
A.
B.
C.
D.
ITEM 4A.
ITEM 5.
A.
B.
C.
D.
E.
ITEM 6.
A.
B.
C.
D.
E.
F.
ITEM 7.
A.
B.
C.
ITEM 8.
A.
B.
ITEM 9.
A.
B.
C.
D.
E.
F.
IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
OFFER STATISTICS AND EXPECTED TIMETABLE
KEY INFORMATION
[Reserved]
Capitalization and Indebtedness
Reasons for the Offer and Use of Proceeds
Risk Factors
INFORMATION ON THE COMPANY
History and Development of the Company
Business Overview
Organizational Structure
Property, Plant and Equipment
UNRESOLVED STAFF COMMENTS
OPERATING AND FINANCIAL REVIEW AND PROSPECTS
Operating Results
Liquidity and Capital Resources
Research and Development, Patents and Licenses
Trend Information
Critical Accounting Estimates
DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
Directors and Senior Management
Compensation
Board Practices
Employees
Share Ownership
Disclosure of a registrant’s action to recover erroneously awarded compensation
MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
Major Shareholders
Related Party Transactions
Interests of Experts and Counsel
FINANCIAL INFORMATION
Financial Statements and Other Financial Information
Significant Changes
THE OFFER AND LISTING
Offer and Listing Details
Plan of Distribution
Markets
Selling Shareholders
Dilution
Expenses of the Issue
i
1
1
1
1
1
1
1
24
24
25
36
36
37
37
37
41
42
43
43
45
45
48
55
57
58
62
62
62
62
62
63
63
63
63
63
63
63
64
64
64
ITEM 10.
A.
B.
C.
D.
E.
F.
G.
H.
I.
J.
ITEM 11.
ITEM 12.
ADDITIONAL INFORMATION
Share Capital
Memorandum and Articles of Association
Material Contracts
Exchange Controls
Taxation
Dividends and Paying Agents
Statement by Experts
Documents on Display
Subsidiary Information
Annual Report to Security Holders
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
64
64
64
65
65
65
72
72
72
72
72
72
73
PART II
ITEM 13.
ITEM 14.
ITEM 15.
ITEM 16.
ITEM 16A.
ITEM 16B.
ITEM 16C.
ITEM 16D.
ITEM 16E.
ITEM 16F.
ITEM 16G.
ITEM 16H.
ITEM 16I
ITEM 16J
ITEM 16K
DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
CONTROLS AND PROCEDURES
RESERVED
AUDIT COMMITTEE FINANCIAL EXPERT
CODE OF ETHICS
PRINCIPAL ACCOUNTANT FEES AND SERVICES
EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES
PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT
CORPORATE GOVERNANCE
MINE SAFETY DISCLOSURE
DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
INSIDER TRADING POLICIES
CYBER SECURITY
74
74
74
74
75
75
75
75
75
75
76
76
76
76
76
76
PART III
ITEM 17.
ITEM 18.
ITEM 19.
SIGNATURES
78
78
78
79
81
82
FINANCIAL STATEMENTS
FINANCIAL STATEMENTS
CONSOLIDATED ENTITY DISCLOSURE STATEMENT
EXHIBITS
ii
PART I
ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
Not applicable.
ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE
Not applicable.
ITEM 3. KEY INFORMATION
A.
[RESERVED]
B.
CAPITALIZATION AND INDEBTEDNESS
Not applicable.
C.
REASONS FOR THE OFFER AND USE OF PROCEEDS
Not applicable.
D.
RISK FACTORS
Investing in our securities involves a high degree of risk and uncertainty. You should carefully consider the risks and uncertainties described
below before investing in our securities. Additional risks and uncertainties not presently known to us or that we believe to be immaterial may also
adversely affect our business. If any of the following risks actually occurs, our business, prospects, financial condition and results of operations could be
harmed. In that case, the daily price of our securities could decline, and you could lose all or part of your investment. These risk factors include:
Risks Related to Our Financial Condition
●
We have a history of operating losses and our management has concluded that factors raise substantial doubt about our ability to continue as
a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit
report for the fiscal year ended June 30, 2024.
●
We will need additional funding to operate our business; such funding may not be available or, if it is available, such financing is likely to
substantially dilute our existing shareholders.
Risks Related to Our Business
●
We are a development stage company engaged in the development of pharmaceutical products and our success in uncertain.
●
We rely on research institutions to conduct our clinical trials and we may not be able to secure and maintain research institutions to conduct
our future trials. The institutions that we work with have their own limits and procedures that will influence or limit our ability to conduct
research and development and the conduct of clinical trials.
●
We are faced with uncertainties related to our research.
●
Clinical trials as they relate to our business are expensive and time consuming and their outcome is uncertain.
●
We may experience delays in our clinical trials that could adversely affect our business and operations.
1
●
We may not be able to complete the development of our products candidates or develop other pharmaceutical products.
●
We may need to prioritise the development of our most promising candidates at the expense of the development of other products.
●
Our research and development efforts will be seriously jeopardised if we are unable to retain key personnel and cultivate key academic and
scientific collaborations.
●
If we are unable to successfully keep pace with technological change or with the advances of our competitors, our technology and products
may become obsolete or non-competitive.
●
Acceptance of our products in the marketplace is uncertain and failure to achieve market acceptance will negatively impact our business and
operations.
●
We have limited large scale manufacturing experience with our product candidates. Delays in manufacturing sufficient quantities of such
materials to the required standards for non-clinical and clinical development may negatively impact our business and operations.
●
The failure to establish sales, marketing and distribution capability would materially impair our ability to successfully market and sell our
pharmaceutical products.
●
If healthcare insurers and other organisations do not pay for our products, or impose limits on reimbursement, our future business may
suffer.
●
We may be exposed to product liability claims, which could harm our business.
●
Breaches of network or information technology security, natural disasters or terrorist attacks could have an adverse effect on our business.
Risks Related to Government Regulation
●
If we do not obtain the necessary governmental approvals, we will be unable to develop or commercialise our pharmaceutical products.
●
We will not be able to commercialise any current or future product candidates if we fail to adequately demonstrate their safety and efficacy.
●
Positive results in previous clinical trials of product candidates may not be replicated in future clinical trials, which could result in
development delays or a failure to obtain marketing approval.
●
Even if approved, any product candidates that we or our subsidiaries may develop and market may be later withdrawn from the market or
subject to promotional limitations.
●
Healthcare reform measures and other statutory or regulatory changes could adversely affect our business.
●
We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act.
2
Risks Related to Intellectual Property
●
Our success depends upon our ability to protect our intellectual property and our proprietary technology, to operate without infringing the
proprietary rights of third parties and to obtain marketing exclusivity for our products and technologies.
●
We may face difficulties in certain jurisdictions in protecting our intellectual property rights, which may diminish the value of our
intellectual property rights in those jurisdictions.
●
Intellectual property rights do not address all potential threats to our competitive advantage.
●
Changes in patent laws or patent jurisprudence could diminish the value of our patents, thereby impairing our ability to protect our products
or product candidates.
●
Confidentiality agreements with employees and others may not adequately prevent disclosure of our trade secrets and protect our other
proprietary information.
Risks Related to Our Compliance with the Sarbanes-Oxley Act of 2002
●
We may fail to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of
2002, which could adversely affect our operating results, investor confidence in our reported financial information, and the market price of
our ordinary shares and ADSs.
●
Material weaknesses in our disclosure controls and procedures could negatively affect shareholder and customer confidence.
Risks Related to Ownership of Our Securities
●
Our stock price may be volatile and the trading markets for our securities is limited.
●
Ownership interest in our company may be further diluted as a result of additional financings.
●
There is a substantial risk that we are a passive foreign investment company, or PFIC, to some U.S. investors which will subject those
investors to adverse tax rules
●
We do not anticipate paying dividends on our ordinary shares.
●
Currency fluctuations may adversely affect the price of our securities.
●
If we fail to maintain compliance with NASDAQ’s continued listing requirements, our shares may be delisted from the NASDAQ Capital
Market.
Risks Related to Our Location in Australia
●
It may be difficult to enforce a judgment in the United States against us and our officers and directors or to assert U.S. securities laws claims
in Australia or serve process on our officers and directors.
●
As a foreign private issuer whose shares are listed on The NASDAQ Capital Market, we may follow certain home country corporate
governance practices instead of certain NASDAQ requirements.
●
We currently do not have a majority of independent directors serving on our Board of Directors, which may afford less protection to our
shareholders than if our Board of Directors had a majority of independent directors.
●
Australian takeovers laws may discourage takeover offers being made for us or may discourage the acquisition of large numbers of our
ordinary shares.
●
Our Constitution and other Australian laws and regulations applicable to us may adversely affect our ability to take actions that could be
beneficial to our shareholders.
3
Risks Related to Our Financial Condition
We have a history of operating losses and our management has concluded that factors raise substantial doubt about our ability to
continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its
audit report for the fiscal year ended June 30, 2024.
We have not sufficiently advanced the development of any of our product candidates to market or generate revenues from their commercial
application and have incurred losses in every period since we began operations in 1997 and reported net losses of A$19,123,464, A$13,806,515 and
A$12,847,061 during the fiscal years ended June 30, 2024, 2023 and 2022 respectively. As of June 30, 2024, our accumulated deficit was
A$214,161,131. We expect to continue incurring losses into the foreseeable future and will need to raise additional capital to continue the development of
our planned research and development programs, and as a result, this creates a material uncertainty that casts significant doubt (or raises substantial doubt
as contemplated by Public Company Accounting Oversight Board (“PCAOB”) standards) on our ability to continue as a going concern and, therefore,
that we may be unable to realize our assets and discharge our liabilities in the normal course of business. Our actual cash requirements may vary
materially from those now planned and will depend upon numerous factors, including:
●
the continued progress of our research and development programs;
●
the timing, scope, results and costs of nonclinical studies and clinical trials;
●
the cost, timing and outcome of regulatory submissions and approvals;
●
determinations as to the commercial potential of our product candidates;
●
our ability to successfully expand our contract manufacturing activities,
●
the cost of corporate overheads, including listed fees;
●
our ability to establish and maintain collaborative arrangements; and
●
the status and timing of competitive developments.
If we fail to generate revenue and eventually become and remain profitable, or if we are unable to fund our continuing losses, our shareholders
could lose all or part of their investments.
We will need additional funding to operate our business; such funding may not be available or, if it is available, such financing is likely
to substantially dilute our existing shareholders.
During the year ended June 30, 2024 we raised A$10,144,682 from the sale of our ordinary shares. We will need to secure additional financing
in order to continue to meet our longer-term business objectives, including advancement of our research and development programs and we may also
require additional funds to pursue regulatory clearances, defend our intellectual property rights, establish commercial scale manufacturing facilities,
develop marketing and sales capabilities and fund operating expenses. We intend to seek such additional funding through public or private financings
and/or through licensing of our assets or strategic alliances or other arrangements with corporate partners.
Until we can generate a sufficient amount of product revenue to finance our cash requ
Share your feedback
Discover